|MOST COMMON ADVERSE REACTIONS IN THE AFFIRM TRIAL1|
|Incidence ≥10% with TYSABRI and ≥2 difference with placebo||TYSABRI
|Urinary tract infections||21%||17%|
|Pain in extremity||16%||14%|
aInfusion reactions were defined as any event that occurred within 2 hours after the start of the infusion.
bPercentage based on female patients only.